| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Angiotensin I, ile(5)- serves as the substrate for the angiotensin-converting enzyme (ACE). It does not have a direct pharmacological target but is the precursor to angiotensin II, which targets the angiotensin II receptor (AT1 receptor). Angiotensin II is a potent vasoconstrictor that regulates blood pressure and fluid balance.
|
|---|---|
| ln Vitro |
In vitro, angiotensin I is used as a substrate to study ACE activity. Its conversion to angiotensin II can be measured in cell-free or cell-based assays. It has no direct biological activity itself. High levels can stimulate catecholamine production, but this is not its primary function.
|
| ln Vivo |
In vivo, angiotensin I is converted to angiotensin II by ACE, which then exerts its effects on blood pressure and fluid balance. It also stimulates the release of aldosterone from the adrenal cortex. Its role is as a precursor to the active hormone angiotensin II.
|
| Enzyme Assay |
The in vitro assay for angiotensin I typically measures its conversion to angiotensin II by ACE. These cell-free assays use purified ACE and measure the production of angiotensin II from angiotensin I using techniques such as HPLC or immunoassay. These assays are used to study ACE activity and to screen for ACE inhibitors.
|
| Cell Assay |
In vitro cellular assays for angiotensin I are not commonly performed, as it is a precursor peptide. Its effects are mediated through its conversion to angiotensin II. Cells expressing ACE can be used to study the conversion of angiotensin I to angiotensin II and the subsequent effects of angiotensin II on the cells.
|
| Animal Protocol |
In vivo animal studies for angiotensin I are conducted to study the renin-angiotensin system. Its effects on blood pressure and fluid balance are mediated through its conversion to angiotensin II. However, specific details of these studies are not extensively detailed in the available literature.
|
| ADME/Pharmacokinetics |
Angiotensin I is a naturally occurring peptide that is rapidly converted to angiotensin II by ACE. Its pharmacokinetic properties are those of a peptide hormone precursor. It is not a drug and is not administered therapeutically.
|
| Toxicity/Toxicokinetics |
Angiotensin I is a naturally occurring peptide and is generally considered safe. It is not a drug and is not intended for therapeutic use. Its toxicity would be related to its conversion to angiotensin II, but specific toxicity data are not applicable.
|
| Additional Infomation |
Angiotensin I is a ten-amino acid peptide formed by the cleavage of renin from angiotensinogen. Angiotensin I itself has no direct biological function, but high concentrations can stimulate the production of catecholamines. After the terminal two amino acids are cleaved by angiotensin-converting enzyme (ACE), it is metabolized into the biologically active byproduct angiotensin II, a potent vasoconstrictor. Angiotensin I is both a neurotransmitter and a human metabolic product. It is a zwitterionic tautomer of angiotensin I. Angiotensin I is a decapeptide derived from the cleavage of renin from its precursor angiotensinogen. The biological activity of angiotensin I is limited. After the removal of the two C-terminal amino acids by angiotensin-converting enzyme, it is converted into the potent vasoconstrictor angiotensin II.
Angiotensin I, ile(5)- is a ten amino acid peptide precursor to angiotensin II. It is formed by renin cleavage of angiotensinogen. It has no direct biological function except as a precursor to angiotensin II. It is used as a research tool in studies of the renin-angiotensin system. |
| Molecular Formula |
C62H89N17O14
|
|---|---|
| Molecular Weight |
1296.47556
|
| Exact Mass |
1295.68
|
| CAS # |
484-42-4
|
| PubChem CID |
3081372
|
| Appearance |
White to off-white solid powder
|
| Density |
1.43 g/cm3
|
| Index of Refraction |
1.667
|
| LogP |
3.832
|
| Hydrogen Bond Donor Count |
16
|
| Hydrogen Bond Acceptor Count |
18
|
| Rotatable Bond Count |
37
|
| Heavy Atom Count |
93
|
| Complexity |
2550
|
| Defined Atom Stereocenter Count |
11
|
| SMILES |
CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC4=CN=CN4)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)N
|
| InChi Key |
ORWYRWWVDCYOMK-HBZPZAIKSA-N
|
| InChi Code |
InChI=1S/C62H89N17O14/c1-7-35(6)51(78-56(87)44(25-37-17-19-40(80)20-18-37)74-58(89)50(34(4)5)77-53(84)42(15-11-21-68-62(64)65)71-52(83)41(63)28-49(81)82)59(90)75-46(27-39-30-67-32-70-39)60(91)79-22-12-16-48(79)57(88)73-43(24-36-13-9-8-10-14-36)54(85)72-45(26-38-29-66-31-69-38)55(86)76-47(61(92)93)23-33(2)3/h8-10,13-14,17-20,29-35,41-48,50-51,80H,7,11-12,15-16,21-28,63H2,1-6H3,(H,66,69)(H,67,70)(H,71,83)(H,72,85)(H,73,88)(H,74,89)(H,75,90)(H,76,86)(H,77,84)(H,78,87)(H,81,82)(H,92,93)(H4,64,65,68)/t35-,41-,42-,43-,44-,45-,46-,47-,48-,50-,51-/m0/s1
|
| Chemical Name |
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-carboxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~25 mg/mL (~19.28 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (77.13 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.7713 mL | 3.8566 mL | 7.7132 mL | |
| 5 mM | 0.1543 mL | 0.7713 mL | 1.5426 mL | |
| 10 mM | 0.0771 mL | 0.3857 mL | 0.7713 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
